(Q39810172)

14 September 2017

title

No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine (English)

1 reference

14 September 2017

0 references

1 reference

1 reference

Jan-Peer Elshoff

1

1 reference

14 September 2017

Willi Cawello

series ordinal

2

1 reference

14 September 2017

Jens-Otto Andreas

series ordinal

3

1 reference

14 September 2017

Marina Braun

series ordinal

4

1 reference

14 September 2017

publication date

12 February 2014

1 reference

Clinical pharmacology in drug development

14 September 2017

published in

1 reference

14 September 2017

volume

3

1 reference

14 September 2017

issue

3

1 reference

14 September 2017

page(s)

187-193

1 reference

A novel dopamine agonist for the transdermal treatment of Parkinson's disease

14 September 2017

cites work

1 reference

Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole

21 January 2018

1 reference

Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study

21 January 2018

1 reference

Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States

21 January 2018

1 reference

Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry

21 January 2018

1 reference

Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery.

21 January 2018

1 reference

Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences

21 January 2018

1 reference

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

21 January 2018

1 reference

Inhibition and induction of human cytochrome P450 (CYP) enzymes

21 January 2018

1 reference

Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive

21 January 2018

1 reference

Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa

21 January 2018

1 reference

Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine

21 January 2018

1 reference

Clinical pharmacology of omeprazole

21 January 2018

1 reference

Rotigotine transdermal delivery for the treatment of Parkinson's disease

21 January 2018

1 reference

7 January 2021

Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study

1 reference

7 January 2021

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial

1 reference

7 January 2021

Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial

1 reference

7 January 2021

Effect of omeprazole on the metabolism of cilostazol

1 reference

7 January 2021

Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies

1 reference

7 January 2021

Identifiers

DOI

10.1002/CPDD.78

1 reference

14 September 2017

1 reference